Ocugen: Positive Prelim Phase 1/2 Results in Retinitis Pigmentoza Trial

 

• Favorable safety and tolerability profile related to OCU400 investigational product candidate
• Initial clinical data from low and medium dose cohorts indicates positive trend in Multi-luminance mobility testing and Best-Corrected Visual Acuity scores for OCU400 treated eyes
• 71.4% (5/7) of OCU400 treated eyes in low and medium dose cohorts experienced at least 1 Lux luminance level improvement in mobility test from baseline
• 66.7% (2/3) of OCU400 treated eyes in low dose cohorts at 9-month follow-up experienced at least 2 Lux luminance level improvement in mobility test from baseline
• Ocugen believes these preliminary data supports potential of modifier gene therapy platform in gene-agnostic treatment of complex and heterogenous inherited genetic diseases

https://www.biospace.com/article/releases/ocugen-announces-positive-preliminary-safety-and-efficacy-results-from-the-phase-1-2-trial-of-ocu400-a-modifier-gene-therapy-product-candidate-for-the-treatment-of-retinitis-pigmentosa-and-leber-congenital-amaurosis/